• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.

BACKGROUND: PEDS-C is the first multicenter placebo-controlled trial for the treatment of chronic hepatitis C (HCV) in childhood that has ever been conducted in the United States (USA). Establishment of the research team, protocol, administrative infrastructure, and ancillary contributors for the pediatric trial took years of planning. PURPOSE: To study the safety and efficacy of pegylated-interferon alpha (PEG-2a) plus ribavirin (RV) with PEG-2a monotherapy in children aged 5 years through 18 years. To assess the health-related quality of life and growth and body composition in children with chronic hepatitis C infection, before, during, and after treatment. METHODS: Eleven centers of pediatric hepatobiliary clinical research were united in a National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) funded grant with financial support from the Food and Drug Administration (FDA) and a corporate sponsor to conduct the treatment trial. LIMITATIONS: The most important initial limitation in the design of this complex study was securing the financial support and infrastructural organization, a process that took several years. Challenges faced by the study group included identifying the optimal study design given the limited study population, and determining what ancillary studies could be incorporated into the treatment trial. CONCLUSIONS: In this article the process taken to design the study and administrative infrastructure, the lessons learned, and the controversial issues deliberated during the planning process are discussed. The evolution of the study and the considerations taken in the development of the protocol are valuable tools which can be applied to pediatric clinical trials in general.

Pubmed ID: 18042575


  • Murray KF
  • Rodrigue JR
  • Gonz├ílez-Peralta RP
  • Shepherd J
  • Barton BA
  • Robuck PR
  • Schwarz KB
  • PEDS-C Clinical Research Network


Clinical trials (London, England)

Publication Data

November 28, 2007

Associated Grants

  • Agency: NIDDK NIH HHS, Id: 1U01DK067767-01
  • Agency: NCRR NIH HHS, Id: 5-M01-RR-000240
  • Agency: NCRR NIH HHS, Id: 5-M01-RR-020359-01
  • Agency: NCRR NIH HHS, Id: M01-RR-00037
  • Agency: NCRR NIH HHS, Id: M01-RR-00069
  • Agency: NCRR NIH HHS, Id: M01-RR-00082
  • Agency: NCRR NIH HHS, Id: M01-RR-00645
  • Agency: NCRR NIH HHS, Id: M01-RR-00750
  • Agency: NCRR NIH HHS, Id: M01-RR-01271
  • Agency: NCRR NIH HHS, Id: M01-RR-02172
  • Agency: NCRR NIH HHS, Id: M01-RR-08084
  • Agency: NIDDK NIH HHS, Id: U01 DK067767
  • Agency: NIDDK NIH HHS, Id: U01 DK067767-01
  • Agency: NIDDK NIH HHS, Id: U01 DK067767-02
  • Agency: NIDDK NIH HHS, Id: U01 DK067767-03
  • Agency: NIDDK NIH HHS, Id: U01-DK-067767-02

Mesh Terms

  • Adolescent
  • Antiviral Agents
  • Child
  • Child, Preschool
  • Hepatitis C, Chronic
  • Humans
  • Interferon-alpha
  • Pediatrics
  • Placebos
  • Polyethylene Glycols
  • Prospective Studies
  • Recombinant Proteins
  • Ribavirin
  • Treatment Outcome
  • United States